Strategic Partnerships Fortis Life Sciences has a track record of collaborating with industry players and recently partnered with Astraea Bio and invested in Deliver Bio. This indicates a strong appetite for co-development and collaboration opportunities that may align with your antibody discovery and translational research capabilities.

Discovery Platform Expansion Abcore specializes in phage display based antibody discovery and single-domain antibodies with naive and immunized libraries. This presents sales potential for clients seeking rapid lead generation, diverse library options, and alternative modalities for difficult targets.

Product Portfolio Growth Recent launches such as AbNano anti-NK cell VHH library and LFA kits with Au nanoparticles demonstrate a diversification into novel reagents and highly sensitive diagnostics. This creates cross-sell opportunities to customers requiring advanced diagnostic tools and translational research support.

Targeted Therapeutics With a founder focus on early-stage drug development and collaborations with large pharma, there is a clear customer base among biotech and pharma companies seeking early discovery and translational solutions, plus potential for expansion into NK cell–targeted therapies and VHH-based modalities.

Financial and Growth Signals Revenue in the mid single-digit tens of millions and ongoing fundraising/grants (including VHH Discovery grants) signal a growth trajectory and willingness to expand capabilities. This suggests prioritizing multi-year collaboration programs, volume engagements, and scalable service packages to capture expanding demand.